Bulk Pharmaceutical API Sources for TAZVERIK

Bulk Pharmaceutical API Sources for TAZVERIK

Vendor	Vendor Homepage	Vendor Sku	API Url
AbaChemScene		CS-1758
MedChemexpress MCE		HY-13803
MolPort		MolPort-035-395-838
4C Pharma Scientific Inc		4CA-0507
CEGChem		QC-11696
Active Biopharma		ABP001111
Axon Medchem		2227

Bulk Active Pharmaceutical Ingredient (API) Sources for Tazverik (Tazemetostat)

Last updated: July 28, 2025

Introduction

Tazverik (tazemetostat) is an innovative oral EZH2 inhibitor developed by Epizyme Inc., approved for treating epithelioid sarcoma and follicular lymphoma. As a targeted epigenetic therapy, its manufacturing hinges on sourcing high-quality bulk API, a critical factor for ensuring efficacy, safety, and regulatory compliance. This article provides a comprehensive analysis of bulk API sources for tazemetostat, detailing manufacturing processes, supplier landscape, quality considerations, and strategic procurement insights relevant to pharmaceutical companies and stakeholders in the supply chain.

Understanding Tazemetostat and Its API

Tazemetostat operates by inhibiting EZH2, a histone methyltransferase implicated in cancer pathogenesis. Its chemical complexity involves a relatively small molecular weight with specific stereochemistry, demanding precision in synthesis. The API synthesis process is multi-step, requiring advanced chemistry and stringent quality controls. The integrity of bulk API directly influences drug product performance, making reliable sourcing paramount.

Manufacturing Process for Tazemetostat API

The synthesis of tazemetostat typically involves:

• Key Starting Materials: Aromatic amines, heterocyclic intermediates, and specialized reagents.
• Synthetic Routes: Multi-step processes including chlorination, cyclization, and stereoselective reactions to achieve the desired stereochemistry.
• Purification and Characterization: Employing chromatography, recrystallization, and spectroscopic analyses to attain pharmaceutical-grade purity (>99% purity).

Manufacturers must operate under strict Good Manufacturing Practices (GMP) compliant facilities to meet regulatory standards set by agencies such as the FDA and EMA.

Global API Suppliers for Tazemetostat

The sourcing landscape is characterized by a handful of specialized chemical manufacturers capable of producing high-purity tazemetostat bulk API at scale.

1. Original Development and Strategic Partners

Epizyme, as the innovator, initially secured API supply through internal manufacturing or collaborations with contract manufacturing organizations (CMOs). These early-stage supplies often emphasize quality and regulatory oversight.

2. Contract Manufacturing Organizations (CMOs)

Leading CMOs globally are engaged to produce tazemetostat API, including:

• Cytiva (formerly part of GE Healthcare): Known for high-quality chemical manufacturing and contract API supply.
• Lonza: Recognized for complex molecule synthesis, including customized API manufacturing, with elevated regulatory standards.
• Stott and Associates: Specialist in small-molecule APIs for oncology indications, with GMP-certified facilities.
• Suven Life Sciences: An Indian-based CMO with capabilities in custom synthesis and API manufacturing for complex small molecules.

This network supports both completed formulations and bulk API for regional and global distribution.

3. Regional API Manufacturers

In Asia, India and China harbor versatile chemical manufacturing sectors capable of producing tazemetostat APIs under stringent quality controls:

• Dr. Reddy's Laboratories: Engaged in advanced synthetic APIs, including for targeted oncology therapies.
• Hikal Ltd.: Specialized in complex APIs with GMP accreditation.
• Siloni Pharma: Indian manufacturer with capabilities in custom synthesis for niche APIs.

In China, companies like Shanghai-based Pharma Value and Kelun Pharmaceutical operate GMP-compliant plants capable of API synthesis for small molecules like tazemetostat.

Quality and Regulatory Considerations

For procurement of tazemetostat API, stringent quality and regulatory compliance are non-negotiable. Key specifications include:

• Purity: ≥99%
• Impurities: Controlled per ICH guidelines
• Residual solvents: Within permissible limits
• Sterility and endotoxin levels: Validated for injectable or oral formulations if applicable

Suppliers should possess valid Certificates of Suitability (CEP), Drug Master Files (DMF), or Drug Substances Master Files (DSMF) accepted by major authorities.

Market Dynamics and Purchasing Strategies

The high cost and complexity of tazemetostat API production influence sourcing strategies:

• Long-term partnerships: Establish reliable supply agreements with trusted CMOs.
• Dual sourcing: Mitigate supply risks by engaging multiple suppliers in different regions.
• Vertical integration: Collaborate with manufacturers capable of both API supply and formulation to streamline supply chains.
• Quality audits: Conduct rigorous evaluations, including on-site audits and review of manufacturing validation data.

Given the specialized nature of tazemetostat, the selection process emphasizes regulatory track record and compliance history over cost alone.

Emerging Trends and Future Outlook

Advances in synthetic methodologies, such as continuous flow chemistry and biocatalysis, could streamline API manufacturing, reduce costs, and enhance scalability. Additionally, investments in GMP facilities in emerging markets are expanding API manufacturing capacity, securing supply chains against disruptions.

With the expansion of indications and potential biosimilar developments, the API source landscape may diversify further, emphasizing sustainable and compliant manufacturing practices.

Conclusion

Securing a reliable source of high-quality tazemetostat API remains critical for pharmaceutical companies aiming to meet demand securely. The landscape involves a combination of original developers, specialized CMOs, and regional manufacturers in Asia. Rigorous quality assurance, regulatory compliance, and strategic supplier relationships underpin successful procurement. As the market evolves, embracing technological innovations and diversifying supplier bases will be essential for maintaining supply stability and competitive advantage.

---

Key Takeaways

• High-quality sourcing of tazemetostat API demands engagement with GMP-certified, regulatory-compliant suppliers worldwide.
• CMO partnerships are prevalent for scalable API production, particularly with companies like Lonza, Cytiva, and Indian manufacturers.
• Quality controls—including purity, impurity profile, and documentation—are non-negotiable to adhere to global regulatory standards.
• Regional manufacturing hubs in India and China have expanded capacity but require stringent validation and oversight.
• Future innovations in synthetic chemistry and increasing manufacturing capacity will influence sourcing strategies, aiming for cost efficiency and supply resilience.

---

FAQs

1. What are the primary challenges in sourcing tazemetostat API?
The main challenges include maintaining high purity standards, complying with regulatory requirements, securing reliable supply chains amid complex synthesis processes, and managing costs associated with GMP manufacturing.

2. Are there multiple suppliers for tazemetostat API or is it limited?
While a limited number of specialized manufacturers can produce the complex API, regional suppliers in India, China, and contract manufacturers globally have expanded options, providing some diversification.

3. How important is regulatory documentation when sourcing API?
Crucial. Regulatory documents such as CEPs and DMFs verify compliance, quality, and manufacturing process integrity, which are essential for approval and pharmacovigilance.

4. Can smaller biotech firms obtain tazemetostat API directly from manufacturers?
Yes, but typically through licensing agreements or partnerships with CMOs. Due to complexity and cost, direct procurement often requires established relationships and regulatory approvals.

5. What future trends could influence the API sourcing landscape for tazemetostat?
Emerging synthetic techniques, increased capacity in Asia, and regulatory harmonization are expected to make sourcing more efficient, cost-effective, and resilient.

---

Sources:

1. Epizyme Inc., Tazverik (tazemetostat) prescribing information, 2023.
2. ICH Guidelines for Quality of Pharmaceutical Substances, 2022.
3. Contract manufacturing companies’ public disclosures and registration dossiers.
4. Market analyses from GlobalData and Pharma Intelligence, 2022–2023.